OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on August 21, 2024. The filing serves to disclose a specific transaction involving the company's Executive Chairman, Gabriele Cerrone, and an entity in which he holds a beneficial interest.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a share purchase transaction rather than a financial performance report.
Material Changes
The primary material change disclosed is the acquisition of 35,000 ordinary shares of OKYO Pharma Ltd by Panetta Partners Limited. The transaction details are as follows:
- Purchaser: Panetta Partners Limited (an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone).
- Quantity: 35,000 ordinary shares.
- Price: US$1.00 per share.
- Exchange: NASDAQ.
- Resulting Ownership: Mr. Cerrone's total shareholding is now 9,671,570 shares, representing 28.58% of the issued share capital.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, guidance, risks, contingencies, or unusual items. The document explicitly states that the attached news announcement is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the current total issued share capital to confirm the 28.58% ownership calculation.
- Review the full text of Exhibit 99.1 (News Announcement) for any additional context regarding the transaction.
- Check subsequent filings for any further changes in beneficial ownership by Mr. Cerrone or Panetta Partners Limited.